Skip to main content
. 2012 Dec;50(12):3952–3959. doi: 10.1128/JCM.01130-12

TABLE 4.

In vitro susceptibilities to fluconazole and voriconazole of 814 yeast strain isolates in the CHIF-NET study, 2010

Organism In vitro susceptibilitya to:
Fluconazole
 Voriconazole
% S % R % S % R
C. albicans 99.3 0.4 99.3 0.7
C. parapsilosis complex
    C. parapsilosis sensu stricto 98.6 1.4 100 0
    C. metapsilosis 100 0 100 0
    C. orthopsilosis 100 0 100 0
    L. elongisporus 100 0 100 0
C. tropicalis 94.3 5.7 94.3 5.7
C. glabrata complex
    C. glabrata sensu stricto NAb 12.2 82.2c 17.8c
    C. nivariensis NA 0 100c 0c
C. krusei 0 100 83.3 11.1
C. guilliermondii 100 0 100 0
C. pelliculosa 50.0 33.3 66.7 8.3
C. lipolytica 10.0 90.0 10.0 90.0
C. lustitaniae 83.3 0 100 0
C. quercitrusa 0 100 100 0
C. catenulata 0 100 0 100
C. fabianii 100 0 100 0
C. famata 100 0 100 0
C. haemulonii 100 0 100 0
C. kefyr 100 0 100 0
C. norvegensis 100 0 100 0
C. neoformans 90.5 6.3 100 0
Other yeast species
    Geotrichum capitum 100 0 100 0
    Kodamaea ohmeri 100 0 100 0
    Meyerozyma caribbica 100 0 100 0
    Rhodotorula mucilaginosa 0 100 0 100
    Trichosporon asahii 85.7 0 100 0
    Trichosporon dermatis 100 0 100 0
a

Susceptibility data were interpreted (i) by species-specific interpretive criteria for C. albicans, C. tropicalis, C. parapsilosis complex, the C. glabrata complex, and C. krusei as described by Pfaller et al. (27, 28) and (ii) in accordance with CLSI document M44-S3 (8) for other yeast species.

b

The latest species-specific interpretive criteria for C. glabrata complex susceptibility to fluconazole were defined as ≤14 mm for R and ≥15 mm for S-DD (28); thus, category S is not applicable (NA) to the C. glabrata complex.

c

As CBPs for C. glabrata complex susceptibility to voriconazole are not available, the ECV (a zone diameter of ≥16 mm) was used to differentiate wild-type (listed in category S) from non-wild-type (listed in category R) strains of this complex, as described by Pfaller et al. (27).